On February 21, Fudan University, Walvax Biotechnology Co.Ltd(300142) and Shanghai lanque biomedical Co., Ltd. signed a tripartite strategic cooperation agreement.
In February 22nd, surging journalists learned from Fudan University that under the agreement, the three parties will play their respective experience advantages in basic research and development, drug development and vaccine industrialization, and establish strategic cooperative relations to achieve technological resources sharing and complementary advantages, so as to jointly promote the development and commercialization of the New Coronavirus mRNA vaccine and strengthen the combination of industry, education and research. Jointly apply for major national scientific research projects and jointly provide continuous support for the development of mRNA new drugs.
Lin Jinzhong, director of “mRNA drug transformation center” of Fudan University, signed a cooperation agreement with representatives of Walvax Biotechnology Co.Ltd(300142) and blue magpie biology.
Jin Li, President of China Academy of Sciences and President of Fudan University, said that the Lin Jinzhong team made a major breakthrough in the field of New Coronavirus mRNA vaccine in early 2020, and made important progress in close cooperation with blue magpie biology for a long time. Fudan University fully supports the transformation of covid-19 vaccine, supports Professor Lin Jinzhong to lead the establishment of the drug R & D center in the University, actively strive for the support of site space policy and other aspects, actively lead the establishment of the country’s first Zhangjiang mRNA international innovation center focusing on mRNA field, and strive to build a basic research center covering mRNA with the support of Shanghai Science and technology, Industry university research innovation platform for drug design and delivery system.
Jin Li introduced that in the future, Fudan University will help mRNA drug research and development in more fields such as filing design and analysis, pharmacy, clinical medicine and public health, and promote the drug research and development achievements of mRNA out of the laboratory and into clinical application.
At the signing ceremony, Lin Jinzhong reported the current research and development progress of covid-19 mutant mRNA chimeric vaccine. Animal experiments and clinical IIT studies have shown that this vaccine has good protection against covid-19 mutants, including Omicron mutant. At the same time, the adverse reactions of two injections were low, which showed high safety. He said that the three parties would jointly promote the ind declaration of the vaccine and realize the commercialization of the product as soon as possible.
Zhang Wenhong, director of the national infectious diseases Medical Center, attended the signing ceremony. He said that the country needs to innovate the independent research and development of vaccines. With the evolution of viruses, the updating and iteration of vaccines is very important. The signing of the trilateral strategic cooperation is an important starting point for future attempts to overcome covid-19, tumors and other human diseases, and a cooperation paradigm of the combination of industry, University, research and application.
